A Deep Dive Into Eosinophilic Esophagitis: Th2 Inhibitors Look Poised for Significant Growth

Research evidence excerpt

A Deep Dive Into Eosinophilic Esophagitis: Th2 Inhibitors Look Poised for Significant Growth

June 22, 2026 A Deep Dive Into Eosinophilic Esophagitis:

Th2 Inhibitors Look Poised for Significant

Growth Julian(617) 345-4055Harrisonjharrison@btig.com

Andrew Kassin

(617) 345-4042 akassin@btig.com WHAT YOU SHOULD KNOW: Eosinophilic esophagitis (EoE) is a chronic, allergicBIOTECHNOLOGY condition driven by a Th2-dominant immune response. Considering Dupixent is the

only approved targeted therapy for EoE and likely generates over $2.5B/yr in EoE alone

(2x the annualized price vs. atopic dermatitis due to more frequent dosing), we thought

a deep dive on the indication made sense. Our KOL checks support high receptivity

for alternatives to Dupixent (dosed QW in EoE) with lower injection burden at parity

or better efficacy; based on a review of the treatment landscape, zumilokibart (fkaINDUSTRY APG777) looks well positioned to command significant market share at Q3M or better

dosing intervals in EoE. Tezspire could be appealing vs. Dupixent although we wonder

how competitive QM would be vs. a Q3M anti-IL-13 Tx option, and the effect size vs.

Dupixent seems reasonably uncertain ahead of Phase 3 data in 2H26 (interestingly not

preceded by any public clinical data, as far as we can tell). Current frontline treatmentREPORT options (e.g., proton pump inhibitors [PPI], steroids, food elimination diets) leave

meaningful unmet need, and EoE's high comorbidity rates with asthma and atopic

dermatitis favor broadly labeled therapies - considering how strong Dupixent's efficacy

is, the goal for most prescribers is to get patients on Th2 inhibitors as fast as possible.

In this report, we discuss EoE pathophysiology, diagnosis, current treatment patterns